Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Perioral Hyaluronidase Injections for Microstomia in Scleroderma Patients
Description
Dr. Polly from Duke University discusses the use of perioral hyaluronidase injections for treating microstomia in patients with scleroderma. She outlines the medical and psychosocial importance of addressing microstomia, highlighting its impact on patients' quality of life and its correlation with oral health issues. Dr. Polly explains that microstomia can worsen throughout the course of scleroderma, but improvements from hyaluronidase can be beneficial. She reviews the mechanisms of hyaluronidase and its historical context in treatment, emphasizing its safety and the positive response seen in patients. The procedure involves inflicting nerve blocks for comfort, diluting hyaluronidase, and administrating multiple injections around the mouth. Dr. Polly shares her personal insights on effective techniques, patient response, and post-procedure care. She concludes that while individual patient needs vary and more research is necessary, hyaluronidase injections offer a viable treatment option that can significantly enhance the quality of life for those affected by microstomia in scleroderma.
View moreConclusions
- Microstomia is a significant concern for patients with systemic sclerosis (scleroderma), impacting their quality of life and is associated with poor prognostic factors in long-term survival.
- Perioral hyaluronidase injections can provide substantial subjective and objective improvements in mouth opening capacity for patients suffering from microstomia due to scleroderma.
- The treatment is generally safe and well-tolerated, with minimal reported adverse effects.
- Nerve blocks enhance the tolerability of hyaluronidase injections for patients, allowing for more effective treatment delivery.
- Improvements in mouth opening tend to plateau after 3 to 5 treatments, suggesting a need for ongoing assessment and potential treatment adjustments over time.
- While initial results are promising, more extensive and prospective studies are needed to determine the long-term efficacy, ideal dosing, and treatment frequency for hyaluronidase in patients with microstomia associated with scleroderma.
- Elgash, May; Kim, Sarah; Swallow, Madisen; Hinchcliff, Monique; Suozzi, Kathleen (2024), "Supplemental Figure 1 for JAAD Research Letter 'Perioral Hyaluronidase Injection for the Treatment of Microstomia in Systemic Sclerosis Patients: A Retrospective Cohort Study'", Mendeley Data, V1, doi: 10.17632/w2y772d9ph.1
- Countryman, Nicholas B.; Hanke, C. William (2012), "Practical Review of Peripheral Nerve Blocks in Dermatologic Surgery of the Face", Curr Derm Rep, 1:49-54, DOI 10.1007/s13671-012-0007-9